This article is more than 5 years old. Information may no longer be current.
HemOnc Today New York to highlight advances in immunotherapy, targeted treatments
Click Here to Manage Email Alerts
HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives and practical insights into the use of immunotherapy and targeted treatments in cancer care.
HemOnc Today New York — scheduled for March 8-10 at Sheraton New York Times Square Hotel — will feature a multidisciplinary faculty that will explore the role of these innovative therapies for the treatment of melanoma, genitourinary cancer, lung cancer, head and neck cancer, and hematologic malignancies.
Program chairs are Sanjiv S. Agarwala, MD, chief of medical oncology and hematology at St. Luke’s Cancer Center and professor of medicine at Temple University; Edward S. Kim, MD, chair of the department of solid tumor oncology and investigational therapeutics at Levine Cancer Institute at Carolinas HealthCare System; and David L. Porter, MD, Jodi Fisher Horowitz professor of leukemia care excellence and director of blood and marrow transplantation at University of Pennsylvania Health System.
HemOnc Today New York will build upon the success of HemOnc Today Melanoma and Cutaneous Malignancies, a 2-day CME meeting held annually in New York from 2011 through 2017. Agarwala served as program director for HemOnc Today Melanoma and Cutaneous Malignancies since the meeting’s inception.
“Given how much immunotherapy specifically has expanded beyond melanoma, it makes sense to now expand the meeting to other tumor types,” Agarwala said. “Just having so many different tumor types covered in regards to targeted therapies and immunotherapy will make for a much more interesting and valuable meeting, and expand the reach of the meeting to oncologists and other cancer professionals who do not just treat melanoma.”
HemOnc Today New York — which will offer 13 hours of CME — will include content pertinent to the entire cancer care team, including hematologists/oncologists from academic or community practices, nurses, physician assistants, researchers and residents/students.
Topics will include how immunotherapy and targeted therapies fit into the treatment paradigm; best practices to ensure optimal treatment timing, sequencing and duration; methods to predict and assess response; and strategies to manage toxicity.
Attendees will leave the meeting with the confidence to use these modalities to provide optimal care while ensuring patient safety.
Agarwala will serve as moderator for Day 1.
The session will begin with an overview of immunotherapy basics and practical considerations, followed by presentations dedicated to melanoma and genitourinary cancer and case studies from those two disciplines.
“In melanoma, there is a fair amount of new data that has come out, especially in adjuvant therapy which we did not have access to until just recently,” Agarwala said.
The first day will conclude with a meet-the-faculty reception.
Kim will moderate Day 2, which will begin with a case-based mini symposium that will explore management of immunotherapy-related adverse events. Additional sessions will be dedicated to lung cancer and head and neck cancer.
“The amount of information that has been accumulating in lung cancer is daunting from a treatment and management standpoint which includes numerous new drug approvals and indications, utilizing biomarkers appropriately and managing toxicities,” Kim said.
Porter will moderate Day 3, which will begin with an exploration of emerging challenges and new data on immunotherapy, including clinical trial enrollment and the need for clinicians to communicate realistic treatment expectations to their patients. Subsequent sessions will address the use of immunotherapy and targeted therapies for the treatment of hematologic malignancies, including leukemia, multiple myeloma and non-Hodgkin lymphoma.
“We have an opportunity to discuss both the newest targeted therapies, as well as exciting new cellular immunotherapies for disease-specific indications,” Porter said. “The ability to go in-depth for a particular disease provides a more practical opportunity to consider direct patient care, more so than if it was providing just a summary of various potential treatment approaches.”
For more information about the meeting, go to www.HemOncTodayNewYork.com. Use the priority code 479-801 to receive discounted registration.
Anyone with questions may call (877) 307-5225, ext. 219 or ext. 476, or send email to registration@contactAMS.com.